Exceptional response to vemurafenib and cobimetinib in anaplastic thyroid cancer 40 years after treatment for papillary thyroid cancer

We present an unusual case of a patient that developed anaplastic thyroid cancer 40 years after treatment for papillary thyroid cancer. The patient presented with locoregional recurrence and distant metastasis. Tumor genotyping identified a V600E mutation. The patient was treated with drugs targetin...

Full description

Saved in:
Bibliographic Details
Published in:International journal of endocrine oncology 2017-11, Vol.4 (4), p.159-165
Main Authors: Green, Patience, Schwartz, Richard H, Shell, Jasmine, Allgauer, Michael, Chong, Daniel, Kebebew, Electron
Format: Article
Language:English
Subjects:
anaplastic thyroid cancer
BRAF
de-differentiation
Family medical history
Iodine
Lymphatic system
Medical imaging
Medical prognosis
Metastasis
Mutation
Neck
NMR
Nuclear magnetic resonance
papillary thyroid cancer
Patients
Surveillance
Thyroid cancer
Tomography
Tumors
vemurafenib
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c245t-dfdca07924ad4ec3802ee438833612ded7eca01cd59c8ed06030885eca80b97d3
cites cdi_FETCH-LOGICAL-c245t-dfdca07924ad4ec3802ee438833612ded7eca01cd59c8ed06030885eca80b97d3
container_end_page 165
container_issue 4
container_start_page 159
container_title International journal of endocrine oncology
container_volume 4
creator Green, Patience
Schwartz, Richard H
Shell, Jasmine
Allgauer, Michael
Chong, Daniel
Kebebew, Electron
description We present an unusual case of a patient that developed anaplastic thyroid cancer 40 years after treatment for papillary thyroid cancer. The patient presented with locoregional recurrence and distant metastasis. Tumor genotyping identified a V600E mutation. The patient was treated with drugs targeting BRAF V600E and MEK (vemurafenib and cobimetinib, respectively). The patient had a remarkable response with the right neck tumor shrinking 81% in size and disappearance of the distant metastases over an 8-month period. The patient underwent surgical resection of the residual tumor with genetic testing of the specimen showing persistent V600E mutation population of cells. Targeted drug therapy has been used with discretion on a case-by-case basis for anaplastic thyroid cancer and may result in good tumor response.
doi_str_mv 10.2217/ije-2017-0016
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2216541212</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2216541212</sourcerecordid><originalsourceid>FETCH-LOGICAL-c245t-dfdca07924ad4ec3802ee438833612ded7eca01cd59c8ed06030885eca80b97d3</originalsourceid><addsrcrecordid>eNp1kE1PxCAQhonRxI3u0TuJ5yrQD-jRbNaPZBMveiYsTCObFipQ4_4Bf7c0NR5MPME7PDNhHoSuKLlhjPJbe4CCEcoLQmhzglaMVHVBBOenv_emPUfrGA8kIzUvKRcr9LX91DAm653qcYA4ehcBJ48_YJiC6sDZPVbOYO33doBk52xdLqmxVzFZjdPbMXibCeU0BFwRfAQVIlZdyjEFUGkAl3DnAx7VaPteheOfrkt01qk-wvrnvECv99uXzWOxe3542tztCs2qOhWmM1oR3rJKmQp0KQgDqEohyrKhzIDhkN-pNnWrBRjSkJIIUeeiIPuWm_ICXS9zx-DfJ4hJHvwU8u5RZotNXVFGWaaKhdLBxxigk2OwQ_61pGTmuMy25WxbzrYz3y58N6UpS9QW8lJySQMYq62Df3q_Ad_8iQQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2216541212</pqid></control><display><type>article</type><title>Exceptional response to vemurafenib and cobimetinib in anaplastic thyroid cancer 40 years after treatment for papillary thyroid cancer</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><creator>Green, Patience ; Schwartz, Richard H ; Shell, Jasmine ; Allgauer, Michael ; Chong, Daniel ; Kebebew, Electron</creator><creatorcontrib>Green, Patience ; Schwartz, Richard H ; Shell, Jasmine ; Allgauer, Michael ; Chong, Daniel ; Kebebew, Electron</creatorcontrib><description>We present an unusual case of a patient that developed anaplastic thyroid cancer 40 years after treatment for papillary thyroid cancer. The patient presented with locoregional recurrence and distant metastasis. Tumor genotyping identified a V600E mutation. The patient was treated with drugs targeting BRAF V600E and MEK (vemurafenib and cobimetinib, respectively). The patient had a remarkable response with the right neck tumor shrinking 81% in size and disappearance of the distant metastases over an 8-month period. The patient underwent surgical resection of the residual tumor with genetic testing of the specimen showing persistent V600E mutation population of cells. Targeted drug therapy has been used with discretion on a case-by-case basis for anaplastic thyroid cancer and may result in good tumor response.</description><identifier>ISSN: 2045-0869</identifier><identifier>EISSN: 2045-0877</identifier><identifier>DOI: 10.2217/ije-2017-0016</identifier><language>eng</language><publisher>London: Future Medicine Ltd</publisher><subject>anaplastic thyroid cancer ; BRAF ; de-differentiation ; Family medical history ; Iodine ; Lymphatic system ; Medical imaging ; Medical prognosis ; Metastasis ; Mutation ; Neck ; NMR ; Nuclear magnetic resonance ; papillary thyroid cancer ; Patients ; Surveillance ; Thyroid cancer ; Tomography ; Tumors ; vemurafenib</subject><ispartof>International journal of endocrine oncology, 2017-11, Vol.4 (4), p.159-165</ispartof><rights>2017 Future Medicine Ltd</rights><rights>2017. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c245t-dfdca07924ad4ec3802ee438833612ded7eca01cd59c8ed06030885eca80b97d3</citedby><cites>FETCH-LOGICAL-c245t-dfdca07924ad4ec3802ee438833612ded7eca01cd59c8ed06030885eca80b97d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2216541212/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2216541212?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590,75126</link.rule.ids></links><search><creatorcontrib>Green, Patience</creatorcontrib><creatorcontrib>Schwartz, Richard H</creatorcontrib><creatorcontrib>Shell, Jasmine</creatorcontrib><creatorcontrib>Allgauer, Michael</creatorcontrib><creatorcontrib>Chong, Daniel</creatorcontrib><creatorcontrib>Kebebew, Electron</creatorcontrib><title>Exceptional response to vemurafenib and cobimetinib in anaplastic thyroid cancer 40 years after treatment for papillary thyroid cancer</title><title>International journal of endocrine oncology</title><description>We present an unusual case of a patient that developed anaplastic thyroid cancer 40 years after treatment for papillary thyroid cancer. The patient presented with locoregional recurrence and distant metastasis. Tumor genotyping identified a V600E mutation. The patient was treated with drugs targeting BRAF V600E and MEK (vemurafenib and cobimetinib, respectively). The patient had a remarkable response with the right neck tumor shrinking 81% in size and disappearance of the distant metastases over an 8-month period. The patient underwent surgical resection of the residual tumor with genetic testing of the specimen showing persistent V600E mutation population of cells. Targeted drug therapy has been used with discretion on a case-by-case basis for anaplastic thyroid cancer and may result in good tumor response.</description><subject>anaplastic thyroid cancer</subject><subject>BRAF</subject><subject>de-differentiation</subject><subject>Family medical history</subject><subject>Iodine</subject><subject>Lymphatic system</subject><subject>Medical imaging</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Mutation</subject><subject>Neck</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>papillary thyroid cancer</subject><subject>Patients</subject><subject>Surveillance</subject><subject>Thyroid cancer</subject><subject>Tomography</subject><subject>Tumors</subject><subject>vemurafenib</subject><issn>2045-0869</issn><issn>2045-0877</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp1kE1PxCAQhonRxI3u0TuJ5yrQD-jRbNaPZBMveiYsTCObFipQ4_4Bf7c0NR5MPME7PDNhHoSuKLlhjPJbe4CCEcoLQmhzglaMVHVBBOenv_emPUfrGA8kIzUvKRcr9LX91DAm653qcYA4ehcBJ48_YJiC6sDZPVbOYO33doBk52xdLqmxVzFZjdPbMXibCeU0BFwRfAQVIlZdyjEFUGkAl3DnAx7VaPteheOfrkt01qk-wvrnvECv99uXzWOxe3542tztCs2qOhWmM1oR3rJKmQp0KQgDqEohyrKhzIDhkN-pNnWrBRjSkJIIUeeiIPuWm_ICXS9zx-DfJ4hJHvwU8u5RZotNXVFGWaaKhdLBxxigk2OwQ_61pGTmuMy25WxbzrYz3y58N6UpS9QW8lJySQMYq62Df3q_Ad_8iQQ</recordid><startdate>20171101</startdate><enddate>20171101</enddate><creator>Green, Patience</creator><creator>Schwartz, Richard H</creator><creator>Shell, Jasmine</creator><creator>Allgauer, Michael</creator><creator>Chong, Daniel</creator><creator>Kebebew, Electron</creator><general>Future Medicine Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20171101</creationdate><title>Exceptional response to vemurafenib and cobimetinib in anaplastic thyroid cancer 40 years after treatment for papillary thyroid cancer</title><author>Green, Patience ; Schwartz, Richard H ; Shell, Jasmine ; Allgauer, Michael ; Chong, Daniel ; Kebebew, Electron</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c245t-dfdca07924ad4ec3802ee438833612ded7eca01cd59c8ed06030885eca80b97d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>anaplastic thyroid cancer</topic><topic>BRAF</topic><topic>de-differentiation</topic><topic>Family medical history</topic><topic>Iodine</topic><topic>Lymphatic system</topic><topic>Medical imaging</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Mutation</topic><topic>Neck</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>papillary thyroid cancer</topic><topic>Patients</topic><topic>Surveillance</topic><topic>Thyroid cancer</topic><topic>Tomography</topic><topic>Tumors</topic><topic>vemurafenib</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Green, Patience</creatorcontrib><creatorcontrib>Schwartz, Richard H</creatorcontrib><creatorcontrib>Shell, Jasmine</creatorcontrib><creatorcontrib>Allgauer, Michael</creatorcontrib><creatorcontrib>Chong, Daniel</creatorcontrib><creatorcontrib>Kebebew, Electron</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>International journal of endocrine oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Green, Patience</au><au>Schwartz, Richard H</au><au>Shell, Jasmine</au><au>Allgauer, Michael</au><au>Chong, Daniel</au><au>Kebebew, Electron</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exceptional response to vemurafenib and cobimetinib in anaplastic thyroid cancer 40 years after treatment for papillary thyroid cancer</atitle><jtitle>International journal of endocrine oncology</jtitle><date>2017-11-01</date><risdate>2017</risdate><volume>4</volume><issue>4</issue><spage>159</spage><epage>165</epage><pages>159-165</pages><issn>2045-0869</issn><eissn>2045-0877</eissn><abstract>We present an unusual case of a patient that developed anaplastic thyroid cancer 40 years after treatment for papillary thyroid cancer. The patient presented with locoregional recurrence and distant metastasis. Tumor genotyping identified a V600E mutation. The patient was treated with drugs targeting BRAF V600E and MEK (vemurafenib and cobimetinib, respectively). The patient had a remarkable response with the right neck tumor shrinking 81% in size and disappearance of the distant metastases over an 8-month period. The patient underwent surgical resection of the residual tumor with genetic testing of the specimen showing persistent V600E mutation population of cells. Targeted drug therapy has been used with discretion on a case-by-case basis for anaplastic thyroid cancer and may result in good tumor response.</abstract><cop>London</cop><pub>Future Medicine Ltd</pub><doi>10.2217/ije-2017-0016</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2045-0869
ispartof International journal of endocrine oncology, 2017-11, Vol.4 (4), p.159-165
issn 2045-0869
2045-0877
language eng
recordid cdi_proquest_journals_2216541212
source Publicly Available Content Database (Proquest) (PQ_SDU_P3)
subjects anaplastic thyroid cancer
BRAF
de-differentiation
Family medical history
Iodine
Lymphatic system
Medical imaging
Medical prognosis
Metastasis
Mutation
Neck
NMR
Nuclear magnetic resonance
papillary thyroid cancer
Patients
Surveillance
Thyroid cancer
Tomography
Tumors
vemurafenib
title Exceptional response to vemurafenib and cobimetinib in anaplastic thyroid cancer 40 years after treatment for papillary thyroid cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T10%3A43%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exceptional%20response%20to%20vemurafenib%20and%20cobimetinib%20in%20anaplastic%20thyroid%20cancer%2040%20years%20after%20treatment%20for%20papillary%20thyroid%20cancer&rft.jtitle=International%20journal%20of%20endocrine%20oncology&rft.au=Green,%20Patience&rft.date=2017-11-01&rft.volume=4&rft.issue=4&rft.spage=159&rft.epage=165&rft.pages=159-165&rft.issn=2045-0869&rft.eissn=2045-0877&rft_id=info:doi/10.2217/ije-2017-0016&rft_dat=%3Cproquest_cross%3E2216541212%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c245t-dfdca07924ad4ec3802ee438833612ded7eca01cd59c8ed06030885eca80b97d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2216541212&rft_id=info:pmid/&rfr_iscdi=true